Clinical research on adefovir dipivoxil combined with thymopentin in the treatment of hepatitis Be antigen positive chronic hepatitis B

Objective To explore the efficacy of adefovir dipivoxil combined with thymopentin in the treatment of chronic hepatitis B.Methods Forty-six patients with hepatitis Be antigen positive chronic hepatitis B were randomly divided into adefovir dipivoxil group and combination group. 24 patients (adefovir dipivoxil group) were treated with adefovir dipivoxil 10 mg/d alone;22 patients (combination group) were treated with combination therapy:after treatment with Adefovir dipivoxil and Thymopentin that was applied with 1 mg intramuscularly per day, third a week for 24 weeks,combined with the treatment of adefovir dipivoxil, all for 48 weeks. Results After 24 weeks, the rate of HBV DNA under detection, HBeAg loss and HBeAg seroconversion rates in combinaiton group were also higher that in adefovir dipivoxil group. The normalization rates of ALT in adefovir dipivoxil group and combinaiton group after 24 weeks and 48 weeks had no difference.After 48 weeks,there were significant difference between adefovir dipivoxil group and combinaiton group such as HBeAg loss and HBeAg seroconversion rates. Conclusions The negative conversion rate of HBV DNA, HBeAg negative rate and HBeAg/HBeAb lipid negative can be remarkabl increased in adefovir dipivoxil combined with thymopentin group. Key words: Hepatitis Be antigen positive chronic hepatitis B;  Adefovir dipivoxil;  Thymopentin;  Combination therapy